
    
      The study will use structural and functional MRIs, daTscans, fluorodeoxyglucose (FDG) PET
      scans, Amyvid PET scans, polysomnographs, neuropsychological testing, cerebrospinal fluid in
      willing participants to distinguish between a diagnosis of Alzheimer's disease, Lewy Body
      dementia, and Parkinson's Disease. All subjects will have a clinical evaluation, physical
      examination including vital signs and orthostatic blood pressures and pulses, neurological
      examination including UPDRS evaluation, genetic blood sample collection, neuropsychological
      testing, polysomnogram, and neuroimaging. The study partner will also be interviewed for
      completion of all of the behavioral and functional measures.
    
  